EZZ Life Science appoints US manufacturing partner

EZZ Life Science enters manufacturing deal with GLSP Inc to serve as its US-based manufacturer
Deal comes as EZZ plans to enter US market in H2 FY25, ensuring enhanced production efficiencies and supply chain logistics
GLSP will manufacture EZZ-branded dietary supplements in compliance with US FDA regulations and ISO-certified quality standards

Special Report: Genomic life science company EZZ Life Science has entered into a manufacturing agreement with GLSP Inc to serve as its US-based manufacturer as it plans to enter the world’s largest healthcare market in H2 FY25.

EZZ Life Science (ASX:EZZ) said establishing a local manufacturing presence in the US marked a significant milestone for the company, ensuring enhanced production efficiencies, improved supply chain logistics and strengthened market positioning in North America.

Under terms of the agreement, GLSP Inc will manufacture EZZ-branded dietary supplements for the North American market in compliance with US Food and Drug Administration (FDA) regulations and ISO-certified quality standards.

In June 2024, EZZ announced that the FDA had approved nine of the company’s products in the food category.

EZZ said the deal ensured that all products would be manufactured to the highest industry standards, meeting strict quality control measures, including third-party laboratory testing for microbiological and heavy metal compliance.

The partnership aligns with EZZ’s broader strategy to expand its global manufacturing and distribution capabilities while catering to the growing demand for high-quality, science-backed health supplements in the US market.

Under further key terms of the agreement manufacturing completion was expected within six to 10 weeks from receipt of all production requirements and initial payment.

EZZ retains full ownership of all trademarks, patents, and formulations, with strict non-disclosure obligations on GLSP Inc.

Project team to facilitate US entry

In its recent H1 FY25 results EZZ said it had appointed a dedicated project team of four staff with backgrounds in marketing and biomedical science as it advanced plans to enter the US market later this financial year.

The company is developing a US-specific brand to avoid confusion with its Australian brand and to address price differences between markets.

It has established a company framework for the US including bank accounts and operational structures to facilitate future growth.

EZZ has identified four high-growth product areas for the US market including probiotics, gut health, women’s health and exercise health.

The company is expected to provide a further update on its US entry in April 2025.

‘Pivotal step’ in global expansion

EZZ’s chairman Glenn Cross said the US manufacturing agreement was an important part of its plan to broaden its overseas markets.

“This agreement represents a pivotal step in our global expansion strategy,” Cross said.

“By manufacturing in the United States, we enhance our ability to serve customers in North America with greater speed and efficiency while maintaining our commitment to premium quality and innovation.

“This partnership strengthens our supply chain resilience and supports our long-term vision for sustainable growth.”

This article was developed in collaboration with EZZ Life Science, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.